5-(3-(1-(1-methylpiperidine-4-yl)-1H-tetrazole-5-ylthio)-6-(trifluoromethyl)quinoxaline-2-yl)thiazole-2-ol | 1337928-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-(3-(1-(1-methylpiperidine-4-yl)-1H-tetrazole-5-ylthio)-6-(trifluoromethyl)quinoxaline-2-yl)thiazole-2-ol
• 英文别名: 5-[3-[1-(1-methylpiperidin-4-yl)tetrazol-5-yl]sulfanyl-6-(trifluoromethyl)quinoxalin-2-yl]-3H-1,3-thiazol-2-one
• CAS: 1337928-68-3
• 化学式: C₁₉H₁₇F₃N₈OS₂
• 分子量: 494.524
• InChiKey: GTMLGHLWNRPVKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  152
• 氢给体数：
  1
• 氢受体数：
  12

文献信息

• [EN] NOVEL QUINOXALINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE QUINOXALINE
  申请人：DONG A PHARM CO LTD

  公开号：WO2011122815A2

  公开（公告）日：2011-10-06

  This invention relates to a novel compound represented by the following Chemical Formula 1, a process for preparing it, and its pharmaceutically approved salt comprising it as an active ingredient. The compound of this invention is GLP 1 receptor regulating low molecular weight compound useful for treatment of metabolic diseases such as diabetes and obesity by regulating the function of glucagon like peptide 1 receptor (GLP 1 receptor) for the disease or disorder carried by GLP 1 since it has the effects on a drop of blood sugar and an improvement of insulin resistance.